Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

LX-2 liver cells

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (3) AMPK (1) Apoptosis (3) Bcl-2 Family (1) c-Myc (1) CaSR (1) Collagen (3) EGFR (1) Endothelin Receptor (1) Epigenetic Reader Domain (1) ERK (2) Ferroptosis (1) Galectin (1) GLUT (1) Glycosyltransferase (1) Hippo (MST) (1) HIV (1) LPL Receptor (2) Mixed Lineage Kinase (1) NF-κB (1) p38 MAPK (1) Phosphatase (1) PI3K (1) Reference Standards (1) RIP kinase (1) TGF-beta/Smad (3) TGF-β Receptor (2) VD/VDR (2) VEGFR (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (2) Endocrinology (1) Infection (1) Inflammation/Immunology (8) Metabolic Disease (8) Neurological Disease (3)

By Targets:

Akt (3)

AMPK (1)

Apoptosis (3)

Bcl-2 Family (1)

c-Myc (1)

CaSR (1)

Collagen (3)

EGFR (1)

Endothelin Receptor (1)

Epigenetic Reader Domain (1)

ERK (2)

Ferroptosis (1)

Galectin (1)

GLUT (1)

Glycosyltransferase (1)

Hippo (MST) (1)

HIV (1)

LPL Receptor (2)

Mixed Lineage Kinase (1)

NF-κB (1)

p38 MAPK (1)

Phosphatase (1)

PI3K (1)

Reference Standards (1)

RIP kinase (1)

TGF-beta/Smad (3)

TGF-β Receptor (2)

VD/VDR (2)

VEGFR (1)

By Research Areas:

Cancer (4)

Cardiovascular Disease (2)

Endocrinology (1)

Infection (1)

Inflammation/Immunology (8)

Metabolic Disease (8)

Neurological Disease (3)

Inhibitors & Agonists

Natural
Products

Targets Recommended: LXR Nuclear Factor of activated T Cells (NFAT) TREM receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-129389

Benzyl-α-GalNAc 5+ Cited Publications	Glycosyltransferase	Cancer
Benzyl-α-GalNAc is a potent O-glycosylation inhibitor. Benzyl-α-GalNAc effectively inhibits the proliferation and activation of LX-2 cells and suppresses the expression of collagen I/III, which has good potential for investigation in liver fibrosis. Benzyl-α-GalNAc also significantly enhances the anti-tumour activity of 5-Fluorouracil (HY-90006) (e.g. pancreatic cancer) by inhibiting O-glycosylation .

HY-W008947

SEW2871 Maximum Cited Publications 9 Publications Verification	LPL Receptor ERK Akt	Neurological Disease Metabolic Disease Inflammation/Immunology
SEW2871 is an orally active, potent, highly selective S1P1 (sphingosine-1-phosphate type 1 receptor) agonist, with an EC₅₀ of 13.8 nM. SEW2871 activates ERK, Akt, and Rac signaling pathways and induces S1P1 internalization and recycling. SEW2871 reduces lymphocyte numbers in blood. SEW2871 can be used for the research of diabetes, Alzheimer’s disease, liver fibrosis, and inflammatory responses .

HY-N0546

Ligustroflavone 2 Publications Verification Nuezhenoside	CaSR RIP kinase Mixed Lineage Kinase TGF-beta/Smad	Cardiovascular Disease Neurological Disease Metabolic Disease Endocrinology
Ligustroflavone is an orally active flavonoid compound. Ligustroflavone can be extracted from Ligustrum lucidum. Ligustroflavone antagonizes the calcium-sensing receptor (CaSR), inhibits the RIPK1/RIPK3/MLKL pathway, and downregulates TGF-β/Smad signaling. Ligustroflavone regulates calcium metabolism, protects bone tissue, reduces cerebral ischemic injury, and inhibits liver fibrosis. Ligustroflavone can be used in the study of diabetic osteoporosis, ischemic stroke, and liver fibrosis .

HY-N7543

Schisantherin D	HIV Endothelin Receptor	Infection Metabolic Disease
Schisantherin D is a lignan. Schisantherin D can be isolated from Kadsura interior. Schisantherin D downregulates the expression of ETBR and inhibits the secretion of ECM and ET-1. Schisantherin D alleviates EtOH + ET-1-induced hepatocyte cytotoxicity. Schisantherin D potently inhibits HIV replication in cells .

HY-169927

Ferroptosis-IN-16	Ferroptosis	Inflammation/Immunology
Ferroptosis-IN-16 (Compound 13l) is a specific inhibitor for ferroptosis with an EC₅₀ of 0.7 nM and 0.9 nM in ES-2 cell and LX-2 cell. Ferroptosis-IN-16 ameliorates Acetaminophen (HY-66005)-induced acute liver injury in mouse model, and exhibits good metabolic stability in mouse liver microsomes .

HY-170543

Dual Galectin-3/EGFR-IN-1	Galectin EGFR Apoptosis	Inflammation/Immunology
Dual Galectin-3/EGFR-IN-1 (Compound 29) is the dual inhibitor for Galectin-3 and EGFR with the K_D of 52.29 μM and 3.31 μM. Dual Galectin-3/EGFR-IN-1 inhibits TGF-β-induced hepatic stellate cell (HSCs) activation, induces apoptosis in LX-2 cell, and exhibits anti-liver fibrotic efficacy .

HY-175033

BRD4-IN-11	Epigenetic Reader Domain Phosphatase c-Myc Apoptosis	Inflammation/Immunology
BRD4-IN-11 is an orally active and selective BRD4 inhibitor (IC₅₀ = 26.35 nM (BD1), IC₅₀ = 72.81 nM (BD2)). BRD4-IN-11 is approximately 3- to 18-fold more potent against BRD4 than againstBRD2, BRD3, and BRDT. BRD4-IN-11 enhances H2S release and inhibits the upregulation of fibrotic markers (α-SMA and fibronectin), c-Myc, and CDC25B. BRD4-IN-11 reduces apoptosis in LO2 hepatocytes. BRD4-IN-11 significantly improves liver and lung function in a hepatopulmonary fibrosis model and can be used to study hepatopulmonary fibrosis .

HY-W008947R

SEW2871 (Standard)	Reference Standards LPL Receptor ERK Akt	Neurological Disease Metabolic Disease Inflammation/Immunology
SEW2871 is an orally active, potent, highly selective S1P1 (sphingosine-1-phosphate type 1 receptor) agonist, with an EC50 of 13.8 nM. SEW2871 activates ERK, Akt, and Rac signaling pathways and induces S1P1 internalization and recycling. SEW2871 reduces lymphocyte numbers in blood. SEW2871 can be used for the research of diabetes, Alzheimer’s disease, liver fibrosis, and inflammatory responses .

HY-145855

J-1063	TGF-β Receptor	Inflammation/Immunology
J-1063 is a potent, selective and orally active ALK5 inhibitor with an IC₅₀ of 0.039 µM. J-1063 shows anti-fibrotic effect by the inhibition of inflammatory infiltration, collagen deposition, and hepatocytes necrosis. J-1063 has the potential for the research of liver fibrosis .

HY-163429

J-1149	TGF-β Receptor p38 MAPK	Inflammation/Immunology Cancer
J-1149 is a potent ALK5 inhibitor, with an IC₅₀ value of 0.017 μM. J-1149 also shows weak p38α MAP kinase inhibitory activity, with an IC₅₀ value of 0.435 μM. J-1149 can be used for liver fibrosis research .

HY-163778

ZM600	NF-κB	Inflammation/Immunology
ZM600 is a potent and orally active antihepatic fibrosis agent. ZM600 decreases the LPS (HY-D1056) induced protein expression of collagen I, α-SM, p-p65. ZM600 has the potential for the research of liver fibrosis .

HY-163403

VEGFR-2-IN-43	VEGFR	Cardiovascular Disease Cancer
VEGFR-2-IN-43 (compound 16) is an orally active inhibitor of VEGFR2, with an IC₅₀ of 39.91 μM. VEGFR-2-IN-43 can be used for wet age-related macular degeneration (w-AMD) disease research .

HY-181808

HSF1/AMPK activator 1	AMPK TGF-beta/Smad Collagen	Metabolic Disease
HSF1/AMPK activator 1 is a compound that modulates the HSF1/AMPK axis and the TGF-β1/Smad signaling pathway. HSF1/AMPK activator 1 exhibits anti-hepatic fibrosis activity and metabolic stability. HSF1/AMPK activator 1 inhibits fibrosis formation and cell proliferation in activated hepatic stellate cells. HSF1/AMPK activator 1 alleviates liver injury and hepatic fibrosis symptoms in fibrotic mice. HSF1/AMPK activator 1 is applicable to research related to hepatic fibrosis .

HY-181486

VDR agonist 5	VD/VDR	Metabolic Disease
VDR agonist 5 is an oral active VDR agonist. VDR agonist 5 activates VDR-mediated signaling to reduce liver fibrosis progression. VDR agonist 5 does not induce hypercalcemia. VDR agonist 5 can be used for the research of hepatic fibrosis .

HY-N11736

12-O-Tiglyl-phorbol 13-dodecanoate	Collagen	Metabolic Disease
12-O-Tiglyl-phorbol 13-dodecanoate (TD13) is a potential inhibitor with anti-hepatic fibrosis activity, and it belongs to a series of derivatives of oral APOL2 inhibitors and anti-hepatic fibrosis agents. It shows no obvious toxicity in preclinical models. Compounds of the 12-O-Tiglyl-phorbol 13-dodecanoate series inhibit the expression of fibronectin, type I collagen and α-smooth muscle actin in hepatic stellate cells. 12-O-Tiglyl-phorbol 13-dodecanoate can be isolated from the Euphorbiaceae plant Euphorbia fischeriana, and it is applicable to the research of hepatic fibrosis .

HY-183069

FKL-137	GLUT PI3K Akt Apoptosis Bcl-2 Family	Cancer
FKL-137 is a GLUT1 and PI3K/AKT signaling pathway inhibitor. FKL-137 binds to GLUT1, reduces glucose uptake and lactate secretion, downregulates glucose metabolism-related proteins, and inhibits erythroleukemia cell proliferation. FKL-137 downregulates PI3K, p-PI3K, AKT, p-AKT levels, disrupts the PI3K/AKT-GLUT1 positive feedback loop, and suppresses erythroleukemia cell proliferation. FKL-137 induces apoptosis via upregulated Bax, Cleaved-PARP and downregulated Bcl-2, PARP. FKL-137 can be used for the research of erythroleukemia .

HY-182038

TGF-β1/Smad3-IN-2	VD/VDR TGF-beta/Smad Collagen Hippo (MST)	Metabolic Disease
TGF-β1/Smad3-IN-2 is an orally active antifibrotic agent. TGF-β1/Smad3-IN-2 has high affinity for VDR and can inhibit the TGFβ/SMAD3 signaling pathway. TGF-β1/Smad3-IN-2 inhibits hepatic stellate cell activation, reduces extracellular matrix deposition, and alleviates liver fibrosis in a bile duct ligation mouse model. TGF-β1/Smad3-IN-2 can be used for the research of liver fibrosis .

Ligustroflavone 2 Publications Verification Nuezhenoside	Flavonoids Oleaceae Classification of Application Fields Flavones Ligustrum lucidum Ait. Phenols Polyphenols Metabolic Disease Plants Disease Research Fields Source Classification	CaSR RIP kinase Mixed Lineage Kinase TGF-beta/Smad
Ligustroflavone is an orally active flavonoid compound. Ligustroflavone can be extracted from Ligustrum lucidum. Ligustroflavone antagonizes the calcium-sensing receptor (CaSR), inhibits the RIPK1/RIPK3/MLKL pathway, and downregulates TGF-β/Smad signaling. Ligustroflavone regulates calcium metabolism, protects bone tissue, reduces cerebral ischemic injury, and inhibits liver fibrosis. Ligustroflavone can be used in the study of diabetic osteoporosis, ischemic stroke, and liver fibrosis .

Schisantherin D	Schisandra sphenanthera Rehd. et Wils Infection Structural Classification Classification of Application Fields Lignans Phenylpropanoids Plants Schisandraceae Disease Research Fields Source Classification	HIV Endothelin Receptor
Schisantherin D is a lignan. Schisantherin D can be isolated from Kadsura interior. Schisantherin D downregulates the expression of ETBR and inhibits the secretion of ECM and ET-1. Schisantherin D alleviates EtOH + ET-1-induced hepatocyte cytotoxicity. Schisantherin D potently inhibits HIV replication in cells .

12-O-Tiglyl-phorbol 13-dodecanoate	Structural Classification Natural Products Euphorbia fischeriana Steud. Euphorbiaceae Plants Source Classification	Collagen
12-O-Tiglyl-phorbol 13-dodecanoate (TD13) is a potential inhibitor with anti-hepatic fibrosis activity, and it belongs to a series of derivatives of oral APOL2 inhibitors and anti-hepatic fibrosis agents. It shows no obvious toxicity in preclinical models. Compounds of the 12-O-Tiglyl-phorbol 13-dodecanoate series inhibit the expression of fibronectin, type I collagen and α-smooth muscle actin in hepatic stellate cells. 12-O-Tiglyl-phorbol 13-dodecanoate can be isolated from the Euphorbiaceae plant Euphorbia fischeriana, and it is applicable to the research of hepatic fibrosis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

LX-2 liver cells

Inhibitors & Agonists

NaturalProducts

Natural
Products